{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Long-term COVID",
      "SARS-CoV-2",
      "Vaccination",
      "bivalent vaccines",
      "investigational drugs",
      "nasal and oral vaccines",
      "use of masks"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "Las predicciones para un pr\u00f3ximo fin de la pandemia de la Organizaci\u00f3n Mundial de la Salud deben interpretarse con precauci\u00f3n. La evidencia actual indica que la eficacia de una cuarta dosis de las vacunas cl\u00e1sicas ARNm (BNT162b2 o mRNA-1273) es baja y de corta duraci\u00f3n para prevenir la infecci\u00f3n de SARS-CoV-2 en su variante predominante (Omicron). No obstante, su eficacia es alta frente a la infecci\u00f3n sintom\u00e1tica grave, hospitalizaci\u00f3n y muerte. Las nuevas vacunas que est\u00e1n siendo introducidas son bivalentes y activas frente a las variantes Omicron. Entre las potenciales nuevas vacunas que se introducir\u00e1n en el pr\u00f3ximo a\u00f1o, se encuentra una vacuna basada en una prote\u00edna recombinante que emula el dominio de uni\u00f3n al receptor de la prote\u00edna Spike en desarrollo por la compa\u00f1\u00eda espa\u00f1ola Hipra, as\u00ed como vacunas de administraci\u00f3n nasal u oral. La informaci\u00f3n disponible apunta a que las vacunas frente al COVID-19 podr\u00e1n administrarse asociadas a la vacunaci\u00f3n antigripal sin particulares complicaciones. Se encuentran en investigaci\u00f3n nuevos f\u00e1rmacos frente a COVID-19 tanto antivirales como anti-inflamatorios pero no parece ocurrir lo mismo con los anticuerpos monoclonales. La indicaci\u00f3n de utilizar mascarillas en algunas circunstancias se mantendr\u00e1 el pr\u00f3ximo a\u00f1o en vista a la acumulaci\u00f3n de datos cient\u00edficos sobre su eficacia. Finalmente, el s\u00edndrome del COVID largo o Post-COVID puede que siga afectando a una proporci\u00f3n muy elevada de los pacientes que sufrieron la enfermedad, requiriendo recursos diagn\u00f3sticos y terap\u00e9uticos combinados."
      ],
      "CopyrightInformation": "\u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/)."
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36510683",
  "DateCompleted": {
    "Year": "2023",
    "Month": "03",
    "Day": "14"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "04",
    "Day": "04"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "12",
        "Day": "13"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.37201/req/122.2022",
      "martin13dec2022"
    ],
    "Journal": {
      "ISSN": "1988-9518",
      "JournalIssue": {
        "Volume": "36",
        "Issue": "2",
        "PubDate": {
          "Year": "2023",
          "Month": "Apr"
        }
      },
      "Title": "Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia",
      "ISOAbbreviation": "Rev Esp Quimioter"
    },
    "ArticleTitle": "Insights for COVID-19 in 2023.",
    "Pagination": {
      "StartPage": "114",
      "EndPage": "124",
      "MedlinePgn": "114-124"
    },
    "Abstract": {
      "AbstractText": [
        "Predictions for a near end of the pandemic by the World Health Organization should be interpreted with caution. Current evidence indicates that the efficacy of a fourth dose of classical mRNA vaccines (BT162b2 or mRNA-1273) is low and short-lived in preventing SARS-CoV-2 infection in its predominant variant (Omicron). However, its efficacy is high against severe symptomatic infection, hospitalization and death. The new vaccines being introduced are bivalent and active against the Omicron variants. Potential new vaccines to be introduced in the coming year include a vaccine based on a recombinant protein that emulates the receptor binding domain of the Spike protein under development by the Spanish company Hipra, as well as vaccines for nasal or oral administration. Available information suggests that vaccines against COVID-19 can be administered in association with influenza vaccination without particular complications. New drugs against COVID-19, both antiviral and anti-inflammatory, are under investigation, but this does not seem to be the case with monoclonal antibodies. The indication to use masks in some circumstances will be maintained next year in view of the accumulation of scientific data on their efficacy. Finally, the long COVID or Post-COVID syndrome may continue to affect a very high proportion of patients who have had the disease, requiring combined diagnostic and therapeutic resources."
      ],
      "CopyrightInformation": "\u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/)."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mart\u00edn S\u00e1nchez",
        "ForeName": "F J",
        "Initials": "FJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mart\u00ednez-Sell\u00e9s",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Molero Garc\u00eda",
        "ForeName": "J M",
        "Initials": "JM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Moreno Guill\u00e9n",
        "ForeName": "S",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Rodr\u00edguez-Artalejo",
        "ForeName": "F J",
        "Initials": "FJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ruiz-Galiana",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cant\u00f3n",
        "ForeName": "R",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "De Lucas Ramos",
        "ForeName": "P",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Garc\u00eda-Botella",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Garc\u00eda-Lled\u00f3",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hern\u00e1ndez-Sampelayo",
        "ForeName": "T",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "G\u00f3mez-Pav\u00f3n",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gonz\u00e1lez Del Castillo",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mart\u00edn-Delgado",
        "ForeName": "M C",
        "Initials": "MC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Servicio de Microbiolog\u00eda Cl\u00ednica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain. emilio.bouza@gmail.com."
          }
        ],
        "LastName": "Bouza",
        "ForeName": "E",
        "Initials": "E"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Spain",
    "MedlineTA": "Rev Esp Quimioter",
    "NlmUniqueID": "9108821",
    "ISSNLinking": "0214-3429"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Post-Acute COVID-19 Syndrome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "The authors declare no conflicts of interest"
}